Analyst firms · Citigroup · ARCT
Citigroup ARCT price target and rating history
Arcturus Therapeutics Holdings Inc. (ARCT) · Health Care
Citigroup rates Arcturus Therapeutics Holdings Inc. (ARCT) Buy with a $20 price target, as of its latest action on Sep 24, 2026. It has published 5 rating actions on ARCT since August 2021, including 2 upgrades and 2 downgrades. Across 3 firms with a ARCT price target in the last 12 months, the median target is $20. Citigroup's target matches it.
- Current rating
- Buy
- Price target
- $20
- Median target, all firms
- $20
- Actions on ARCT
- 5
Citigroup price target on ARCT
Every Citigroup rating on ARCT
- Sep 24, 2026
- Oct 23, 2025
- Nov 3, 2022
- Apr 21, 2022
- Aug 25, 2021
How other firms rate ARCT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Citigroup | Buy | $20 | Sep 24, 2026 |
| B. Riley Securities | Buy | $22 | Mar 18, 2026 |
| Roth Capital | Buy | $20 | Jan 23, 2026 |
Questions about Citigroup and ARCT
- What is Citigroup's price target for ARCT?
- Citigroup's latest stated price target for Arcturus Therapeutics Holdings Inc. (ARCT) is $20, from its action on Sep 24, 2026.
- What is Citigroup's rating on ARCT?
- Citigroup rates ARCT Buy, a bullish rating, as of Sep 24, 2026.
- When did Citigroup last change its view on ARCT?
- On Sep 24, 2026, Citigroup upgrades to Buy from Neutral, price target $20.
- How does Citigroup's ARCT target compare with other analysts?
- Across 3 firms with a ARCT price target in the last 12 months, the median target is $20. Citigroup's target matches it.
More ARCT rating histories
All Citigroup ratingsARCT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.